Apnimed Swings To Q2 Profit, Eyes February 2027 FDA Decision On AD109 In Obstructive Sleep Apnea

Apnimed reported a swing to net income in Q2 2026 ended June 30, versus a net loss in the prior-year period. The profitability improvement is positive for the late-stage clinical pharmaceutical company, although the article provides no revenue, EPS, cash-balance, or guidance figures to assess the durability or scale of the result.